Browsing Bergen Open Research Archive by Author "Waha, Andreas"
Now showing items 1-3 of 3
-
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
Rahman, Mohummad Aminur; Gras Navarro, Andrea; Brekke, Jorunn; Engelsen, Agnete; Bindesbøll, Christian; Sarowar, Shahin; Bahador, Marzieh; Bifulco, Ersilia; Goplen, Dorota; Waha, Andreas; Lie, Stein Atle; Gjertsen, Bjørn Tore; Selheim, Frode; Enger, Per Øyvind; Simonsen, Anne; Enger, Martha Chekenya (Peer reviewed; Journal article, 2019-08-15)Background Resistance to temozolomide (TMZ) is due in part to enhanced DNA repair mediated by high expression of O6-methyl guanine DNA methyltransferase (MGMT) that is often characterised by unmethylated promoter. Here, ... -
Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level
Kmiecik, Justyna; Poli, Aurélie; Brons, Nicolaas H.C.; Waha, Andreas; Eide, Geir Egil; Enger, Per Øyvind; Zimmer, Jacques; Chekenya, Martha (Peer reviewed; Journal article, 2013-11-15)We characterized GBM patients' tumor and systemic immune contexture with aim to reveal themechanisms of immunological escape, their impact on patient outcome, and identify targets for immunotherapy. Increased CD3+ T-cell ... -
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
Rahman, Mohummad Aminur; Brekke, Jorunn; Arnesen, Victoria Smith; Hannisdal, Marianne; Navarro, Andrea Gras; Waha, Andreas; Herfindal, Lars; Rygh, Cecilie Brekke; Bratland, Eirik; Brandal, Petter; Haász, Judit; Oltedal, Leif; Miletic, Hrvoje; Lundervold, Arvid; Lie, Stein Atle; Goplen, Dorota; Chekenya, Martha (Journal article; Peer reviewed, 2020)Background Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O6 methylguanine ...